Skip to main navigation menu Skip to main content Skip to site footer

Technical comment

Vol. 154 No. 10 (2024)

Technical comment on: Trottmann M, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data

  • Caroline Arber+
  • Gabriela Baerlocher
  • Yves Chalandon
  • Michael Daskalakis
  • Michel Duchosal
  • Martin Fehr
  • Sabine Gerull
  • Tayfun Güngör
  • Gayathri Nair
  • Thomas Pabst
  • Jakob R. Passweg
  • Barbara Piccolruaz
  • Christoph Renner
  • Axel Ruefer
  • Dominik Schneidawind
  • Georg Stüssi
  • Sacha Zeerleder
  • Jörg P. Halter
DOI
https://doi.org/10.57187/s.3704
Cite this as:
Swiss Med Wkly. 2024;154:3704
Published
03.10.2024

Summary

No abstract available.

References

  1. Trottmann M, Blozik E, Hilbig M, LoVerdi D, Pedruzzi M, Scherer T, et al. Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data. Swiss Med Wkly. 2023 Sep;153(9):3441. doi: https://doi.org/10.57187/s.3441 DOI: https://doi.org/10.57187/s.3441
  2. Passweg JR, Baldomero H, Ansari M, Arber C, Chalandon Y, Daskalakis M, et al.; Swiss Blood Stem Cell Transplantation Group (SBST). Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021. Hematol Oncol. 2024 Jan;42(1):e3241. doi: https://doi.org/10.1002/hon.3241 DOI: https://doi.org/10.1002/hon.3241
  3. Duchosal MA, et al. Développements récents en hématologie, Teil 1. Swiss Medical Forum, 2023. doi: https://doi.org/10.4414/fms.2023.09462 DOI: https://doi.org/10.4414/fms.2023.09462
  4. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al.; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan;380(1):45–56. doi: https://doi.org/10.1056/NEJMoa1804980 DOI: https://doi.org/10.1056/NEJMoa1804980
  5. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017 Dec;377(26):2531–44. doi: https://doi.org/10.1056/NEJMoa1707447 DOI: https://doi.org/10.1056/NEJMoa1707447
  6. Di Blasi R, Thieblemont C, Haioun C, Sackmann Sala L, Mayaud AC, Diez-Andreu P, et al. Healthcare Resource Use (HCRU) and Associated Costs Among Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CAR-T Cells in France – A Real-World Study Using Data From PMSI. Value Health. 2022;25(12):S79–80. doi: https://doi.org/10.1016/j.jval.2022.09.390 DOI: https://doi.org/10.1016/j.jval.2022.09.390
  7. Nicolopoulos K, Moshi M, Min M, Stringer D, Vreugdenburg T. The CAR T-cell therapies tisagenlecleucel (Kymriah®) and axicabtagene ciloleucel (Yescarta®) for the treatment of B-cell acute lymphoblastic leukaemia, diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma. Berne: Federal Office for Public Health - HTA Report, 2024. Internet: https://www.bag.admin.ch/bag/en/home/versicherungen/krankenversicherung/krankenversicherung-leistungen-tarife/hta/hta-projekte/carttherapien.html

Most read articles by the same author(s)

<< < 1 2 3 > >>